Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Suppression of bone remodeling associated with long-term bisphosphonate treatment is mediated by microRNA-30a-5p.

Tytuł:
Suppression of bone remodeling associated with long-term bisphosphonate treatment is mediated by microRNA-30a-5p.
Autorzy:
Li X; Institute of Integrated Chinese and Western Medicine, The Hospital Affiliated to Jiangnan University, Wuxi, Jiangsu, China.
Xu R; Institute of Integrated Chinese and Western Medicine, The Hospital Affiliated to Jiangnan University, Wuxi, Jiangsu, China.
Ye JX; Institute of Integrated Chinese and Western Medicine, The Hospital Affiliated to Jiangnan University, Wuxi, Jiangsu, China.; Department of Orthopaedics and Central Laboratory, The Third Hospital Affiliated to Nantong University, Wuxi, Jiangsu, China.
Yuan FL; Institute of Integrated Chinese and Western Medicine, The Hospital Affiliated to Jiangnan University, Wuxi, Jiangsu, China.; Department of Orthopaedics, The Hospital Affiliated to Jiangnan University, Wuxi, Jiangsu, China.
Źródło:
Bioengineered [Bioengineered] 2022 Apr; Vol. 13 (4), pp. 9741-9753.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin : Landes Bioscience
MeSH Terms:
Bone Remodeling*/drug effects
Diphosphonates*/pharmacology
Diphosphonates*/therapeutic use
MicroRNAs*/genetics
MicroRNAs*/metabolism
Animals ; Antagomirs/metabolism ; Female ; Humans ; Mice ; Osteoblasts/metabolism
References:
Calcif Tissue Int. 2015 Nov;97(5):495-505. (PMID: 26163235)
Best Pract Res Clin Obstet Gynaecol. 2002 Jun;16(3):309-27. (PMID: 12099665)
J Bone Miner Res. 2007 Oct;22(10):1479-91. (PMID: 17663640)
Bioengineered. 2022 Mar;13(3):5709-5723. (PMID: 35188450)
Osteoporos Int. 2015 May;26(5):1605-18. (PMID: 25603795)
Nat Commun. 2019 Mar 21;10(1):1299. (PMID: 30898996)
Int J Mol Sci. 2017 Jun 23;18(7):. (PMID: 28644396)
Curr Osteoporos Rep. 2021 Apr;19(2):182-188. (PMID: 33528743)
Kidney Int. 2012 Oct;82(8):833-5. (PMID: 23018824)
J Bone Miner Res. 2011 Mar;26(3):441-51. (PMID: 20928874)
Biosci Rep. 2020 Jun 26;40(6):. (PMID: 32436939)
Bone. 2015 Jun;75:128-37. (PMID: 25708053)
Nat Commun. 2016 Mar 07;7:10872. (PMID: 26947250)
J Bone Miner Res. 2014 Aug;29(8):1715-7. (PMID: 24932802)
Lancet. 2011 Apr 9;377(9773):1276-87. (PMID: 21450337)
Nat Med. 2013 Jan;19(1):93-100. (PMID: 23223004)
PLoS One. 2013 Dec 09;8(12):e73159. (PMID: 24348985)
Blood. 2017 Apr 13;129(15):2061-2069. (PMID: 28179276)
Bone. 2020 Aug;137:115444. (PMID: 32447074)
J Bone Miner Res. 2017 Jan;32(1):46-59. (PMID: 27391172)
Bone. 2014 Jan;58:126-35. (PMID: 24120384)
J Bone Miner Res. 2016 Oct;31(10):1910. (PMID: 27759931)
Bioengineered. 2021 Dec;12(1):8173-8185. (PMID: 34672248)
Arch Oral Biol. 2019 Jan;97:176-184. (PMID: 30391794)
Nat Rev Genet. 2004 Jul;5(7):522-31. (PMID: 15211354)
Menopause. 2006 May-Jun;13(3):340-67; quiz 368-9. (PMID: 16735931)
Bone. 2019 May;122:52-75. (PMID: 30772601)
Mayo Clin Proc. 2009 Jul;84(7):632-7; quiz 638. (PMID: 19567717)
Contributed Indexing:
Keywords: MiRNA; Osteoporosis; bisphosphonate; bone loss; osteoblast
Substance Nomenclature:
0 (Antagomirs)
0 (Diphosphonates)
0 (MIRN30a microRNA, human)
0 (MIRN30a microRNA, mouse)
0 (MicroRNAs)
Entry Date(s):
Date Created: 20220412 Date Completed: 20220414 Latest Revision: 20220716
Update Code:
20240105
PubMed Central ID:
PMC9161941
DOI:
10.1080/21655979.2022.2060584
PMID:
35412438
Czasopismo naukowe
Oral bisphosphonates (BPs) are a first-line treatment for osteoporosis. It is becoming a hot topic to identify new indicators for the early prediction of therapeutic effects and adverse reactions during the long-term use of BPs. To determine whether microRNA (miRNA) expression is modulated by long-term BPs treatment, we performed miRNA expression profiling analysis in patients receiving long-term BP treatment for postmenopausal OP. To assess the effect of BPs on miRNA expression, we used an Affymetrix Genechip miRNA array to analyze serum samples obtained from postmenopausal OP patients on long-term BP treatment and healthy controls. MiRNAs affected by BPs and their predicted targets were examined. We also investigated the effects of miRNA on osteoblast differentiation in vitro and on ovariectomy-induced bone loss in vivo. We observed that the level of miR-30a-5p was significantly increased in patients receiving long-term BP treatment for postmenopausal OP. Furthermore, miR-30a-5p was negatively correlated with bone formation. Consistent with this, in vitro osteoblast activity and matrix mineralization were increased by an antagomir of miR-30a-5p and decreased by an agomir of miR-30a-5p. We also found that miR-30a-5p directly targeted RUNX1 to inhibit osteoblastic differentiation. Consistent with the in vitro results, miR-30a-5p antagomir administration promoted bone formation in ovariectomized mice. Our findings identified miR-30a-5p as a novel mediator of long-term BP treatment that regulates bone formation in postmenopausal OP patients.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies